EX-10.1
from 10-Q
26 pages
1.introduction. This Turning Point Therapeutics, Inc. Severance Benefit Plan – C-Suite (The “Plan”) Is Established by Turning Point Therapeutics, Inc. (The “Company”) Effective September 18, 2017 (The “Effective Date”), Amended Effective September 29, 2018, February 20, 2019 and July 25, 2019 and Amended and Restated February 15, 2020 and May 4, 2021. the Plan Provides for Severance Benefits to Selected Employees of the Company. This Document Also Constitutes the Summary Plan Description for the Plan. 2. Definitions. for Purposes of the Plan, the Following Terms Are Defined as Follows: (A) “Board” Means the Board of Directors of the Company
12/34/56
EX-10.20
from 10-K
66 pages
This License Agreement (This “Agreement”) Is Made as of January 10, 2021 (The “Effective Date”), by and Between Turning Point Therapeutics, Inc., a Corporation Organized and Existing Under the Laws of Delaware (“TPTX”), Located at 10628 Science Center Drive, Suite 200, San Diego, California 92121, United States of America, and Zai Lab (Shanghai) Co., Ltd., an Exempted Company Organized and Existing Under the Laws of P.R. of China, Located at 4f, Bldg 1, Jinchuang Plaza, 4560 Jinke Rd, Shanghai, China, 201210 (“Zai”). TPTX and Zai Are Referred to in This Agreement Individually as a “Party” and Collectively as the “Parties.”
12/34/56
